Wertel I, Surówka J, Polak G, Barczyński B, Bednarek W, Jakubowicz-Gil J, Bojarska-Junak A, Kotarski J
I Chair and Department of Oncological Gynaecology and Gynaecology, Medical University of Lublin, Staszica 16, 20-081, Lublin, Poland,
Tumour Biol. 2015 Jun;36(6):4811-7. doi: 10.1007/s13277-015-3133-8. Epub 2015 Feb 3.
The study was undertaken to evaluate macrophage-derived chemokine (CCL22) levels in the peritoneal fluid (PF) and plasma of patients with ovarian cancer (n = 93) in relation to regulatory T cells (Tregs; n = 75). The peritoneal fluid CCL22 concentrations were significantly higher in epithelial ovarian cancer (EOC) patients than in patients with benign tumors-serous cystadenoma (n = 32). There was no difference in plasma levels of CCL22 in EOC patients compared with the non-cancer and healthy volunteers (n = 10). There were no significant differences in the plasma and PF CCL22 levels based on tumor grade. However, women with stage IV FIGO (International Federation of Gynecologists and Obstetricians) had significantly higher plasma CCL22 levels than patients with stages I and III. Women with stage I FIGO had significantly higher PF CCL22 levels than patients with stages II and III. Women with endometrioid cystadenocarcinoma had higher PF CCL22 levels than women with undifferentiated carcinoma. The percentage of tumor-infiltrating Tregs (11.06 %) was significantly higher compared to PF (3.05 %) and peripheral blood (PB) (2.01 %). Moreover, the percentage of Tregs was higher in the PF than in the PB of EOC patients. There were no significant differences in the PB, PF, and tumor-infiltrating Tregs percentage based on tumor stage, grade, or histology. Elevated levels of CCL22 found in the ascites could create a chemokine gradient aiding in Treg cells migration. Increased Tregs percentage in the local microenvironment of ovarian cancer might be an important mechanism of immunosuppression.
本研究旨在评估卵巢癌患者（n = 93）腹腔液（PF）和血浆中巨噬细胞衍生趋化因子（CCL22）水平与调节性T细胞（Tregs；n = 75）的关系。上皮性卵巢癌（EOC）患者腹腔液CCL22浓度显著高于良性肿瘤——浆液性囊腺瘤患者（n = 32）。与非癌症患者和健康志愿者（n = 10）相比，EOC患者血浆CCL22水平无差异。基于肿瘤分级，血浆和PF中CCL22水平无显著差异。然而，国际妇产科联合会（FIGO）IV期女性的血浆CCL22水平显著高于I期和III期患者。FIGO I期女性的PF CCL22水平显著高于II期和III期患者。子宫内膜样囊腺癌女性的PF CCL22水平高于未分化癌女性。肿瘤浸润Tregs的百分比（11.06%）显著高于PF（3.05%）和外周血（PB）（2.01%）。此外，EOC患者PF中Tregs的百分比高于PB。基于肿瘤分期、分级或组织学，PB、PF和肿瘤浸润Tregs百分比无显著差异。腹水中CCL22水平升高可形成趋化因子梯度，有助于Treg细胞迁移。卵巢癌局部微环境中Tregs百分比增加可能是免疫抑制的重要机制。
